AstraZeneca Scraps Late-Stage Lung Cancer Trial After Data Setback

3-line summary

• AstraZeneca scrapped a late-stage lung cancer clinical trial after a data setback, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.